Introduction
Adeno-associated viral (AAV) vectors belong to the parvovirus family and are arguably the simplest of all vectors, containing only a small (4.7 kb) single-stranded DNA molecule encoding the therapeutic protein flanked by inverted terminal repeats. The viral DNA is packaged in a capsid composed of three proteins designated VP1-3. 1 Once inside the cell, the genome is converted to double-stranded transcriptionally active DNA, which is stabilized as a predominantly non-integrated episomal form. 2, 3 The first and still most commonly used AAV capsid serotype used in gene therapy applications is serotype 2. To date, 11 different serotypes, designated AAV1-11, and over 100 variants have been isolated from human or nonhuman primate tissues. 4 This has led to the development of new pseudo-typed AAV vectors that incorporate the basic AAV2 vector DNA cassette packaged into a wide range of different capsids. 5 Serotypes differ in tropism according to their respective receptor usage. AAV2 enters the cells through attachment to the cell surface receptor heparan sulfate proteoglycan. aVb 5 integrin and fibroblast growth factor receptor 1 function as coreceptors. 6, 7 AAV5 utilizes platelet-derived growth factor receptors for cell entry. 8 Recently, the laminin receptor has been identified as a receptor for AAV serotypes 8, 3 and 9. Laminin receptors are constitutively expressed in many clinically relevant tissues, which provides a molecular explanation for AAV8's broad tissue tropism. 9 In addition to the development of novel serotypes, recent advances have been made to overcome the size restriction of the small AAV genome. Trans-splicing vectors have been developed, which are able to efficiently package twice the size of the vector genome. 10 Finally, AAV gene-targeting vectors have also recently been used successfully to correct naturally occurring gene mutations through homologous recombination. 11 Rather than delivering an episomal copy of a therapeutic gene, this novel approach allows efficient, specific, nonmutagenic gene repair in vivo. 12 The advantage of a corrected sequence is that it allows expression under physiological circumstances.
The development of recombinant AAV vectors in gene therapy applications is in large part due to their lack of pathogenicity, low immunogenicity and ability to establish long-term transgene expression. Furthermore several cures have been reported in animal models of human diseases. [13] [14] [15] [16] [17] [18] However, complications of treatment related to immune responses against the vectors have emerged as serious obstacles for successful translations to humans.
The immune system has evolved as a sophisticated and versatile defense system with long-term memory, aimed at efficiently identifying and removing non-self. Although considerable progress has been made in defining and overcoming the immune response to AAV vectors, some obstacles remain and new problems have emerged. In the following review, recent advances in understanding the host innate and adaptive immune responses to AAV vector components and transgenes in animals and humans will be reviewed and strategies to avoid such responses will be discussed.
Innate immunity
The innate immune system consists of protein mediators and innate cells that play a key role in the recognition and early response to infectious agents. Recognition of viruses including gene therapy vectors by innate immune cells, such as macrophages and dendritic cells (DCs) leads to the secretion of inflammatory mediators such as chemokines and cytokines, which enhance antigen processing and display of viral epitopes on major histocompatibility complex (MHC) molecules. Inflammatory gene expression also upregulates costimulatory molecules at the cell surface of antigenpresenting cells (APCs), such as DCs, thereby enabling these cells to activate T and B cells. 19 Innate immune cells recognize pathogens through extra-and intracellular pattern recognition receptors. These receptors include the toll-like receptors, the antiviral cytoplasmic helicases (RIG-I and MDA5) or NOD-like receptors, which are specialized microbial and viral sensors. 20, 21 Once activated, innate receptors regulate type I interferon (IFN) and nuclear factor-kB-dependent gene expression, or process cytokines such as pro-interleukin (IL)-1b to their active and secreted forms. AAV vectors do not appear to engage pattern recognition receptors such as toll-like receptors, 22 fail to induce type I IFN responses 23 and do not induce IL-1b processing (Zaiss and Muruve, unpublished observations).
However, other innate antiviral mechanisms exist that can effectively modulate virus and viral vector biology. Recently, APOBEC3A (hA3A) has been identified as a potent inhibitor of AAV replication. 24 APOBEC3 proteins constitute a powerful mechanism of vertebrate innate immunity by providing intracellular resistance to retrovirus replication. 25 Human APOBEC3A has the ability to enter the nucleus and shows specificity for singlestranded DNA. The inhibition of AAV by hA3A is the first example of an APOBEC protein that targets a virus that replicates exclusively in the nucleus without passing through an RNA intermediate. The mechanism of hA3A inhibition of AAV is not entirely clear. APOBEC3A might bind to single-stranded viral DNA, thereby interfering with the completion of DNA synthesis. Potential roles for hA3A in AAV immunity in vivo will be dependent upon further analysis of its cell-type expression and AAV tropism. For example, it would be interesting to determine if APOBEC3A plays a role in the aberrant AAV transduction of DCs and macrophages. Macrophages are activated by AAV vectors in vitro and play a key role in initiating AAV-induced innate immune responses in mice. 26 However, despite the interaction, macrophages are poorly transduced by AAV vectors. 27 Although the explanation is currently unclear, it is possible that monocyte/macrophage expressed APOBE-C3A limits AAV transduction in this cell type. 24 In contrast, AAV transduction will not be affected in cell types or tissues that do not express APOBEC3A.
The interaction of innate cells with viral vectors likely requires or is modified by serum opsonins. Recent studies show that AAV uptake by macrophages and the activation of inflammatory gene expression are enhanced in the presence of serum, but returns to baseline when the serum is heat-inactivated or depleted of complement component C3, indicating that AAV interacts significantly with complement. 27 In fact immunoprecipitation studies confirm that the AAV vector capsid is associated with iC3b in human serum. C3b generated through either spontaneous hydrolysis of C3 by the alternative pathway or by activation of the classical pathway of complement is deposited at specific surfaces and has two possible fates. In the presence of a membrane bound or soluble cofactor of the regulator of complement activation family, such as factor H, factor I is recruited and C3b is rapidly converted to iC3b, which abrogates further complement activation. In the absence of a cofactor, factor B is recruited, resulting in the formation of the C3 convertase and proceeding of complement activation. 28 Since factor H co-immunoprecipitated with both, AAVC3b complexes and with AAV alone, it is likely that iC3b is generated on the viral capsid, a possible mechanism used by AAV to limit the innate response. 27 Many pathogens have evolved mechanisms to evade direct activation of the complement system by mimicking host surfaces, thereby recruiting factor H. 29 Consistent with these findings, AAV vectors fail to activate the alternative pathway of complement. 27 Although avoiding complement activation, pathogens opsonized with iC3b are still subject to immune adherence and phagocytosis through engagement with complement receptors on immune cells. Thus, the interaction between AAV and the complement system still has immunological consequences. Co-engagement of the complement receptor complex with the B-cell antigen receptor enhances B-cell responses by lowering substantially the threshold for B-cell activation, resulting in enhanced antibody production. 30, 31 The development of neutralizing antibodies to AAV vector in mice deficient of complement receptors 1 and 2 or complement component C3 is significantly impaired compared to wild-type controls. 27 Furthermore, recent research has shown that complement can modulate T-cell responses through direct interaction with the T cell itself and indirectly through the alteration of APCs (APCs). The engagement of complement receptors on APCs modulates their maturation status and their chemokine and cytokine expression profiles, which in turn influence the T-cell response induced during antigen presentation. 32 iC3b and factor H deposition on pathogens inhibit the strong and effective activation of the complement cascade and create a relatively non-inflammatory microenvironment, which might in part be responsible for the failure of AAV to induce DC maturation. These findings might also explain why AAV vectors so often induce immune tolerance to encoded transgenes as discussed in the next section.
Immunity to the encoded transgene
The development of immune responses to the encoded therapeutic transgene can be detrimental to the host. It not only could prevent further gene therapy attempts but also the administration of therapeutic proteins by means other than gene therapy. 33, 34 T-cell activation is induced
Immunity to AAV AK Zaiss and DA Muruve through the presentation of antigen by mature APCs in lymph nodes or secondary lymphoid structures to the T cell. The nature of the antigen, the APC and the microenvironment largely determine whether the activated T cells will then migrate to an inflammatory site. The manner in which an antigen reaches the molecule for presentation by APCs can occur through two distinct pathways. Antigen that is endogenously generated by the cellular machinery within the APC enters the direct presentation pathway, leading to display of peptide epitopes on MHC class I molecules. Mature APCs that display peptide antigens through MHC-I molecules activate cytotoxic CD8+ T lymphocytes (CTLs). Since AAV vector transduction and transgene expression in DCs are relatively inefficient, CD8+ T-cell responses to AAV-encoded transgenes are often avoided. [35] [36] [37] [38] [39] [40] Protein from sources exogenous to the cell is generally endocytosed or phagocytosed and displayed on MHC class II molecules, leading to the activation of CD4+T helper cells and B cells. However, exogenous antigen, although taken up by endocytosis or phagocytosis can also reach MHC-I in a less understood manner termed crosspresentation. Cross-presentation is believed to be the predominant mechanism by which AAV-encoded transgenes induce CD8+ T-cell immune responses. 38, 41, 42 Since both B-and T-cell responses to AAV-encoded transgenes rely on uptake by APCs, whether or not an immune response is mounted depends in a large part on the abundance of the transgene, the kinetics of its expression, as well as its immunogenicity rather than on the vector serotype. Therefore, responses are generally dose dependent 43 and can be avoided by a more restricted expression, for example by using tissuespecific promoters as opposed to systemic general promoters. [44] [45] [46] Independent from these findings, evidence is accumulating that targeting AAV vectors specifically to the liver seems to induce tolerance to the transgene product. 13, 47, 48 Tolerance induction in liver: the role of regulatory T cells
Injection of an AAV2 vector expressing human factor IX (hF.IX) intramuscularly into out-bred immunocompetent mice induces antibodies resulting in diminished transgene expression. In contrast, hepatic gene transfer failed to elicit consistent strong immune responses to factor IX in the same mice. 49 Similarly, macaques infused via the hepatic artery with AAV8-hF.IX failed to develop antibodies to hF.IX. 50 Moscioni et al. 51 achieved longterm expression (41 year) of ornithine transcarbamylase in livers of ornithine transcarbamylase-deficient mice using AAV serotypes 7-9. The mice were tolerant to antigenic challenge 3 weeks after injections, whereas control mice were not. In contrast, rhesus macaques (three of three) formed neutralizing antibodies to hF.IX using an adenovirus vector. 52 Further studies provided evidence that the induction of immune tolerance to AAVencoded therapeutic transgene products in liver is mediated by regulatory T cells. 53 Dobrzynski et al. 53 demonstrated induction of antigenspecific CD4+ T-cell tolerance to a secreted transgene product (ovalbumin, ova) in ova-specific T-cell receptor transgenic mice by hepatic AAV-mediated gene transfer. Transduced mice failed to mount an immune response to the ova transgene. Furthermore, TCR+CD4+ cell populations were reduced in numbers, anergic to ova antigen in vitro and enriched for CD25+ regulatory T cells. Similarly, Cao et al. 54 also demonstrated induction of immune tolerance to coagulation factor IX (F.IX) by hepatic AAV gene transfer. Adoptive lymphocyte transfers from these mice indicated the induction of CD4+CD25+ regulatory T cells that suppressed antibody formation to F.IX. Moreover, in vivo depletion of CD4+CD25+ regulatory T cells leads to antibody formation to the F.IX transgene product, which strongly suggests that these regulatory cells were required for tolerance induction. This was further confirmed by the use of an immunosuppressive regimen during AAV2 hepatic gene transfer in nonhuman primates, which resulted in the inhibition of regulatory T cells and the development of neutralizing antibodies to the transgene product. 48 These studies highlight the importance of regulatory T cells in maintaining tolerance to the transgene product. Furthermore, immune tolerance induction through AAV-mediated liver-directed gene transfer has enabled supplementary therapies such as enzyme replacement therapy 55 or muscle-directed gene transfer. 56 How AAV liver-directed gene transfer leads to the development of tolerance and the induction of regulatory T cells is not clear.
AAV as vaccine carrier: a paradox?
Despite being associated with low immunogenicity and tolerance induction, AAV vectors have been used successfully as vaccine carriers to induce transgene product-specific immune responses in various animal models. 41, 42, 57, 58 In one recent study, Xin et al. 59 compared the ability of most of the common AAV serotypes (serotypes 1, 2, 3, 4, 5, 7 and 8) to function as vaccine in a HIV-1gp160 antigen trial in mice. Although all AAV serotypes were able to induce humoral and T-cell responses to HIV-gp160, AAV5 vector transduced mouse and human DCs more efficiently and elicited higher HIVspecific cell-mediated immune responses compared to the other serotypes.
Some studies however indicate that AAV might not be a perfect candidate for use in vaccinations. Lin et al. 60 also evaluated the potential of vectors based on AAV as vaccine carriers for the HIV-1 protein gag. A vector based on AAV8 demonstrated strong gag CD8(+) T-cell and antibody responses in mice. However, no CD8(+) T-cell response was generated when the animals were boosted with an adenovirus-expressing gag. This stood in contrast to the response when adenovirus was used for primary vaccination. The authors suggested possible reasons for the aberrant activation of CD8(+) T cells by AAV including chronic antigen expression, which lead to T-cell exhaustion. Similar results were obtained in mice where AAV vectors expressing the gene encoding HIV-1 gag stimulated gag-specific CD8(+) T cells, but these T cells then equally failed to expand after a booster immunization. AAV vector-induced CD8(+) T cells proliferated poorly, produced low levels of IFN-g in response to gag stimulation, and upregulated immunoinhibitory molecules, such as death ligand-1. The unresponsiveness of the CD8(+) T cells was reversed by placing them in an antigen-free environment, again suggesting T-cell exhaustion as a possible mechanism. 61 Furthermore, in another study using AAV as a vaccine delivery system against two strains of malaria, AAV Immunity to AAV AK Zaiss and DA Muruve vectors failed to stimulate an adequate level of antimalarial protective immunity. Although AAV encoding malarial antigens stimulated long-term antigen-specific antibody responses after intramuscular injections, the vaccination was not protective against infection and efforts taken to augment antibody responses were unsuccessful. 62 In summary, vaccination has been achieved in numerous animal models, but mainly for very immunogenic (predominantly viral) antigens. The successes in using AAV vectors as vaccines achieved in animal models might not be as easily translated into humans, however, due to the ability of AAV to induce functionally impaired T cells and tolerance. On the other hand, using new serotypes, such as AAV5 for gene therapy applications other than vaccination should be considered with caution, since the enhanced ability to transduce DCs might translate into undesired immune responses toward the therapeutic protein.
Immunity to the AAV capsid AAV leads to the development of neutralizing antibodies directed against the vector capsid, which prevents readministration of AAV vectors of the same serotype. Therefore, the prevalence of neutralizing antibodies in humans previously exposed to AAV represents one major obstacle for successful AAV gene therapy applications.
AAV capsid antibodies: a persistent challenge
To test human anti-AAV antibodies in their ability to decrease AAV transduction in vivo, Scallan et al. reconstituted SCID mice with pooled human immunoglobulin of predetermined titers, followed by AAV2-F.IX vector administration. Unexpectedly, AAV2 neutralizing titers lower than 1:10 were sufficient to neutralize up to 20 Â 10 12 vg/kg of AAV2 vectors in vivo, as demonstrated by a lack of F.IX expression. These results indicate that neutralizing antibodies at titers lower than 1:10 can abrogate liver transduction by high doses of AAV2-hF.IX. Direct liver and portal vein injection did not significantly improve AAV escape from neutralization compared with intravenous delivery, neither did further increasing the delivery rate. 63 In non-human primates, who are the natural host for AAV8, a neutralizing antibody titer as low as 1:5 resulted in a complete absence of transgene expression and absence of vector DNAs in all tissues examined after AAV8-F.IX administration via the hepatic artery. Animals with undetectable neutralizing antibodies were effectively transduced by AAV8-F.IX. 50 The presence of neutralizing antibodies to the AAV capsid has similar profound effects on liver transduction in humans as shown by a recent clinical trial for hemophilia B; a titer of 1:17 in one subject was sufficient to prevent transduction. 64 Overcoming pre-existing humoral responses to the capsid. Immunosuppression during primary exposure can prevent the development of capsid antibodies in naïve animals; 65, 66 in contrast, overcoming pre-existing antibody titers might not be straightforward. Several strategies have been suggested to overcome pre-existing antibody titers. Murphy et al. established the clearance kinetics for serotypes 2 and 8 in cell culture and in mice, to define the time period in which the vectors are susceptible to antibody-mediated neutralization. Clearance rates for both AAV2 and AAV8 vectors were between 2 and 4 h in mice, when administered via the portal vein and tail vein, respectively. This suggests that antibodies would have to be removed or blocked for at least 4 h to prevent neutralization. 67 Capsid modifications. Mutations in the capsid can avoid neutralizing antibody responses. 68 A strategy employed by a number of groups has been to use site-directed mutagenesis to disrupt neutralizing epitopes on AAV capsids. 68, 69 The most promising approach was used by Mahesri et al. A large ( 410 6 ) AAV2 library was generated with randomly distributed capsid mutations. A highthroughput approach was then used to select for AAV variants with the ability to evade neutralizing antibodies by delivering genes in the presence of anti-AAV serum. This approach directs viral evolution to generate 'designer' gene delivery vectors with specified, enhanced properties and yielded several neutralizing antibody-evading phenotypes. 70 Serotype switching. Numerous studies suggest that neutralizing capsid antibodies against one serotype have only limited cross-reactivity to other serotypes, thereby enabling sequential transduction of alternative serotypes. 5, 71, 72 Riviere et al. 73 tested AAV vectors for their ability to escape capsid neutralization based on serotypes 1, 2 and 5 in immunocompetent mice and found that all three AAVs were inhibited by neutralizing antibodies upon secondary injections using the identical serotype. In contrast, gene expression was unaffected when alternative serotypes were used. The same was shown in non-human primates using AAV5. 74 Intravenous administration of a self-complementary AAV5 vector encoding the human F.IX gene resulted in comparable levels of circulating F.IX in macaques with or without pre-existing immunity to AAV8. This confirms that alternative serotypes can circumvent pre-existing naturally acquired immunity to AAV in the non-human primate model. However, the substitution of AAV2 with AAV8, 5 or 6 to evade pre-existing antibody titers to AAV2 in humans might not be successful on all occasions. Sequences closely related to AAV8 have been isolated from a variety of human tissues and AAV8 neutralizing antibodies have been detected in the human population, although with markedly less frequency than AAV2 (3.8 vs 20%). 5 Halbert et al. 75 measured neutralizing antibodies against AAV type 2, 5, and 6 vectors in serum from children and adults with cystic fibrosis, and from normal adults. The results indicated that 20-30% of adults were seropositive for AAV6 and 10-20% displayed antibodies to AAV5, compared to 30% for AAV2. Children were also seropositive for AAV type 2, 5 or 6 (4-15%). These studies suggest that alternative serotypes further in the phylogenetic tree might be necessary to overcome blocking pre-existing AAV antibodies in humans. A promising candidate in this regard might be the rhesus AAVrh.10 serotype. AAVrh.10-pseudotyped vector retained high-level, long-lasting expression patterns equivalent to other AAV serotypes and prior immunization with AAV2 or AAV5 did not interfere with the efficacy of subsequent AAVrh.10 vector administration, Immunity to AAV AK Zaiss and DA Muruve although each serotype did elicit an immune response that was sufficient to block a second dose of a vector of the same serotype. 76 A caprine AAV capsid (AAV-Go.1) has also been generated and shown to escape preexisting immunity to AAV in humans. 77 Most intriguing is the finding that AAV9 could be readministered to murine nasal and lung airway epithelia despite high levels of circulating neutralizing antibodies without diminution of transgene expression. In contrast, AAV5 was neutralized resulting in abrogated transgene expression upon secondary exposure. 78 
T-cell responses to the AAV capsid: a new challenge
Numerous pre-clinical studies in experimental animals showed that AAV2 vectors could achieve long-term expression of the transgene product in immunocompetent experimental animals, including mice, rats, dogs and non-human primates without eliciting a cell-mediated adaptive immune response that limits gene expression. 13, 47, 79, 80 Consequently, with these promising preclinical data in mind, the first liver-directed gene therapy phase I/II trial in humans was initiated involving delivery of human F.IX for the treatment of hemophilia. 64 An AAV2 vector expressing human F.IX under the control of a liver-specific promoter was infused through the hepatic artery. The first subject enrolled at the predicted therapeutic dose (2 Â 10 À12 vp/kg) showed therapeutic levels of F.IX expression. Furthermore, vector infusion was not associated with acute or long-lasting toxicity, demonstrating that AAV2 can transduce human liver and leads to expression of F.IX at therapeutic levels. However, in contrast to the long-lasting expression in experimental animals, F.IX expression at therapeutic levels in humans started to decline 4 weeks after vector infusion, and gradually returned to pretreatment levels within 2 months. The gradual decline in F.IX was accompanied by a transient elevation of liver transaminase enzymes (transaminitis). A subject treated subsequently with a fivefold lower vector dose also developed transaminitis. 64 The role of memory T cells. In the above studies, toxic or infectious causes for liver transaminitis and other causes not related to the gene transfer were ruled out. No antibody to F.IX was found in the affected patients and analysis of T-cell responses in peripheral blood mononuclear cell demonstrated IFN-g production in response to AAV capsid peptides but not in response to F.IX peptides, suggesting that the loss of therapeutic gene expression was not due to immune responses to the F.IX transgene. 64 Instead, the analysis suggested that a T-cell response was mounted to the AAV2 capsid. Identification of the AAV capsid peptide epitope responsible allowed the synthesis of MHC-I pentamers for the quantification of capsid-specific CD8+ T cells, indicating a pool of memory T cells. 81 These findings suggest that MHC-I displayed capsid epitopes on AAV-transduced hepatocytes were recognized and lysed by CD8 + effector T cells. Interestingly, unlike F.IX, AAV capsid antigens are not synthesized in transduced cells, since there are no coding sequences for expression of capsid in the vector genome. Thus, capsid epitopes likely reached MHC class I molecules via the cross-presentation pathway. This is further suggested by studies describing the ubiquitination of AAV capsids upon transduction that may target input capsids to the proteasome leading to MHC-I display. 82, 83 In humans, initial infection with AAV2 takes place in the context of a helper virus infection such as adenovirus, which causes a robust inflammatory response likely initiating the formation of memory CD8+ T cells to both viruses. On re-exposure to AAV capsid, these memory CD8+ T cells are activated and eliminate transduced hepatocytes, which display AAV capsid epitopes on MHC-I.
In general, memory T cells develop once a primary infection is controlled, and act as sentinels of the immune system capable of rapidly purging the host of recurrent infections by the same pathogen. In contrast to naïve lymphocytes, memory T cells do not need to be primed again by APCs. It is sufficient to encounter antigen to reactivate these cells, resulting in the rapid expansion and presence of potent cytotoxic lymphocytes. A series of follow-up experiments indicated that healthy human subjects carry AAV capsid-specific CD8+ T cells, which can be expanded and that show high cytolytic activity against cells that display capsid antigen. 81 Furthermore, AAV2-induced human T cells proliferated upon exposure to alternate AAV serotypes (AAV8 and AAV1), indicating that AAV2 memory T cells cross-react with other serotypes. 81 Additional evidence that humans carry a pool of expandable AAV-specific memory CD8+ T cells comes from in vitro expansion of peripheral blood mononuclear cell or splenocytes from healthy donors with AAV capsid peptides that showed 28% (2/7) of peripheral blood mononuclear cell and 60% (9/15) of spleen samples were positive for T-cell responses to AAV2. 84 In an attempt to develop a model of the hepatotoxicity and loss of F.IX expression seen in humans, Jiang et al. chose AAV8 as a vector in non-human primates. Nonhuman primates are natural hosts for AAV8, so animals infused with an AAV8 vector might activate a memory T-cell response to the vector capsid equivalent to the memory response to AAV2 seen in humans. The result from the study, however, demonstrated that even high doses of AAV8 vectors encoding F.IX failed to provoke liver transaminitis in the animals. 50 Several studies demonstrated that AAV capsid-specific CTLs also do not appear to play a role in elimination of AAVtransduced cells in mouse models. 85, 86 The fact that capsid-specific T cells in animal models were unable to lyse AAV-transduced hepatocytes sparked a scientific debate about alternative explanations other than capsid cross-presentation. One interesting consideration was that latent AAV genomes, which occur endogenously with high abundance in humans, might have become activated by homologous recombination with vector genomes-leading to the expression of capsid proteins. 87 Nevertheless, these studies highlight the difficulties that exist in translating pre-clinical animal data to humans.
Overcoming AAV capsid T-cell responses. Serotype switching. It might not be possible to avoid memory T-cell responses to the AAV capsid by switching serotypes. AAV2 capsid-primed CD8+ memory T cells in humans cross-react with epitopes from AAV8 and AAV1 capsids and result in expansion of functional CD8 + cytotoxic lymphocytes that are indistinguishable from those elicited by AAV2 capsid epitopes. 81 The same was found for AAV capsid epitopes in mice. T cells that are Immunity to AAV AK Zaiss and DA Muruve generated in response to exposure to the AAV capsid of one serotype (AAV2) were able to recognize peptides from conserved protein sequences from another nonhuman serotype (AAV8). 88 This is not surprising considering that T cells recognize short peptides (9 amino acids in length) that are generated by proteolytic digestion of the protein and that AAV capsid protein sequences of different serotypes are highly conserved. The AAV8 capsid amino-acid sequence, for example, is 83% conserved compared to the AAV2 sequence. 5 Moreover, since antigen presentation by DCs is not essential for re-activation of memory CD8+ T cells, differential uptake of vectors by DCs would be irrelevant to humans with immunological memory to AAV2. 89 However, it is possible that differences in kinetics of vector uncoating among various AAV serotypes may influence the presentation of capsid epitopes on MHC-I molecules, thereby inducing differential CTL responses toward transduced cells. 90 Vectors based on AAV serotype 2 have been reported to uncoat slowly, thus potentially allowing processed capsid peptides to be presented by MHC-I. Serotypes that uncoat quickly might not display capsid proteins for the same amount of time or avoid presentation on the MHC-I surface of transduced cells. It will be important to understand to what extent cross-reactivity of T cells specific to AAV capsids occurs in humans with pre-existing immunity to AAV2.
Immunosuppression. The AAV capsid, needed to deliver the therapeutic gene, is only transiently present in the transduced cell, since it is not encoded in the vector and should be gradually cleared. One possible solution to block the host T-cell response is transient immunosuppression, to allow capsid clearance and subsequent long-term expression of the donated gene. Immunosuppressants such as cyclosporine, sirolimus and daclizumab suppress cytotoxic T-cell responses by inhibiting either IL-2 production or the response of cells to IL-2. These drugs are usually used in concert with mycophenolate mofetil (MMF), an inhibitor of de novo guanosine nucleotide synthesis that affects B-and T-cell proliferation. Another commonly used immunosuppressive agent is antithymocyte globulin, an infusion of rabbit-derived antibodies against human T cells. Wang et al. 91 demonstrated that direct intramuscular injection of AAV2 or AAV6 in immunocompetent, random-bred dogs resulted in a robust cellular immune response to the capsid, even when an empty AAV6 vector preparation was injected. However, 3 months of immunosuppression with a combination of antithymocyte globulin, cyclosporine and MMF immediately following vector injection was sufficient to permit long-term and sustained expression of canine micro-dystrophin in the skeletal muscle in the same dog model. 92 Another anti-T-cell regimen was tested in a non-human primate model of AAV-mediated hF.IX administration via the hepatic artery. Since nonhuman primates did not develop capsid-specific CTLs regardless of the immunosuppression, the immunemodulating drug regimen could only be tested for safety. The administration of a two-drug regimen consisting of MMF and tacrolimus did not result in any side effects and was tolerated well, suggesting that it is safe. 50 Not all studies, however, prove the efficacy of an immunosuppressive approach. A three-drug regimen consisting of MMF, sirolimus and daclizumab failed to prevent the formation of inhibitory antibodies to human F.IX, and was accompanied by a dramatic drop in the population of regulatory T cells. 48 These studies suggest that immune suppression protocols need to be carefully adjusted to produce the desired immune-modulating effect in vivo.
Conclusions and future directions
Several main paradigms seem to be supported by the current body of work with regard to AAV immunity. AAV-mediated gene transfer has not been associated with significant inflammatory responses or toxicity in animal models and humans irrespective of the presence of neutralizing antibodies. Furthermore, liver-directed AAV gene transfer is associated with the induction of tolerance rather than immunity, resulting in sustained expression of therapeutic genes. Transgene expression in liver is also more efficient compared to muscle. This was confirmed in a human clinical trial for hemophilia B. 64 Therapeutic levels of F.IX were achieved through AAV2 liver-directed gene transfer (at least temporarily). Although transgene expression could be detected over long periods of time, AAV2 muscle gene therapy in humans resulted in only subtherapeutic levels of factor IX. 16, 93 Whether the increased efficiency of therapeutic gene expression by alternative serotypes of AAV obtained in animal models, particularly in mice, can be translated to humans remains to be determined.
Obstacles of AAV-mediated gene therapy include the predisposition of neutralizing antibodies, which represent more of a problem than originally anticipated. Even very low titers (1:5-1:10) can completely abrogate transduction with high titers of vectors. 50, 63, 64 A new challenge is related to the observed immunotoxicity and loss of F.IX expression in two subjects during the clinical trial in which an AAV vector was introduced into the liver of hemophilia B patients. 64 Activated T-cell populations were identified with specificity toward epitopes on the AAV2 capsid, likely responsible for the clearance of transduced hepatocytes. 64, 81 The dosing of high amounts of vector particles in a gene therapy setting might make cross-presentation physiologically relevant. Data that have been assembled indicate that as much as 60% of the population harbor capsid-specific memory T-cell populations. 84 The significance of these findings for systemic approaches of AAV gene delivery is substantial. Future investigation will determine whether different serotypes or short-term immunosuppression can circumvent such responses.
Despite widespread immunity in the general population to common AAV serotypes, so far the majority of studies have addressed the interaction of viral vectors with naïve animals. Future investigation needs to define the role of antiviral antibodies in mediating AAV interactions with the immune system. While antibodies inhibit viral entry in epithelial-derived target cells, immunoglobulin-or complement-opsonized virus is targeted to and taken up by innate immune cells (including APCs, such as DCs) through Fc receptors and complement receptors. Fc receptor crosslinking or the targeting of opsonized virus particles to innate immune cells and the engagement of innate receptors may induce signal transduction events that can lead to Immunity to AAV AK Zaiss and DA Muruve inflammatory gene expression and responses that are very different from those in naïve hosts. The role of the innate immune system does not end at the onset of adaptive immunity. There is likely ongoing cross-talk between the innate and adaptive immune system in the course of an infection, which determines the overall outcome of an immune response.
Other opportunities for future investigation lie in elucidating why memory T-cell responses differ between humans and animals. AAV capsid processing and display of peptides on MHC-I molecules might be different in mouse and human hepatocytes or human T cells might be more sensitive to T-cell receptor stimulation. 94 Alternatively, the generation, number, priming or homing of memory T cells might be different in humans compared to animals. A clinical study of AAV2-F.IX co-administered with transient immunosuppression to block the T-cell response to capsid will show if the AAV capsid-directed T-cell response could be blocked. 95 In addition, whether AAV8 can escape T-cell responses will be tested in an upcoming clinical trial of an AAV8 vector expressing F.IX. 95 These studies should help to determine whether long-term correction could be achieved with liver-directed gene transfer of an AAV vector in humans.
Despite drawbacks, AAV remains one of the most promising candidates for therapeutic gene transfer. The immune system with its seemingly incomprehensive complexity cannot be underestimated. However, the more we understand in detail on how the different elements of immunity orchestrate a response to the vectors, the safer the gene therapy applications will become and more the strategies for manipulation of such responses that will be brought to light. Given the disparities between animal and human studies, clinical trials are essential to guide future investigation. With more human studies currently underway, clinical AAV gene therapy applications might be closer than anticipated.
